Table 4. In-hospital cardiac events of all study patients .
| Variable | Uric acid ≤ 5.7 (n = 291) | Uric acid > 5.7 (n = 143) | p value |
| Cardiovascular mortality, n (%) | 5 (1.7) | 18 (12.6) | < 0.001 |
| Reinfarction, n (%) | 18 (6.2) | 7 (4.9) | 0.6 |
| Target-vessel revascularization, n (%) | 18 (6.2) | 7 (4.9) | 0.6 |
| MACE, n (%) | 22 (7.6) | 24 (16.8) | 0.003 |
| Stroke, n (%) | 1 (0.3) | 2 (1.4) | 0.22 |
| Cardiopulmonary resuscitation, n (%) | 6 (2.1) | 22 (15.4) | < 0.001 |
| Dialysis, n (%) | 1 (0.3) | 2 (1.4) | 0.22 |
| Advanced heart failure, n (%) | 13 (4.7) | 30 (21) | < 0.001 |
| Cardiogenic shock, n (%) | 7 (2.4) | 20 (14) | < 0.001 |
| Inotropic agent usage,n (%) | 13 (4.5) | 23 (16.1) | < 0.001 |
| IABP usage, n (%) | 5 (1.76) | 12 (8.4) | 0.001 |
| Atrial fibrillation, n (%) | 04 (1.4) | 7 (4.9) | 0.03 |
| Transient pace, n (%) | 5 (1.7) | 9 (6.3) | 0.01 |
| Gastrointestinal bleeding, n (%) | 0 (0) | 2 (1.4) | 0.04 |
| Blood transfusion | 1 (0.3) | 2 (1.4) | 0.22 |
| Ventilator necessity | 5 (1.7) | 16 (11.2) | < 0.001 |
| No-reflow phenomenon | 45 (15.5) | 48 (33.6) | < 0.001 |
| LVEF, % (SD) | 49.2 ± 9.2 | 45 ± 11.1 | < 0.001 |
IABP, intra-aortic balloon pump; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events (cardiovascular mortality, reinfarction, target-vessel revascularization).